Products Meningococcal C Conjugate Vaccine
Meningococcal C Conjugate Vaccine Phase 3 Completed 📈 Rising Prevention of Meningococcal Infection
Prevention of Meningococcal Infection
About Meningococcal C Conjugate Vaccine Meningococcal C Conjugate Vaccine is a phase 3 stage product being developed by Novartis for Prevention of Meningococcal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00310674. Target conditions include Prevention of Meningococcal Infection.
Clinical Trials (6) NCT ID Phase Status Start Completion Indication NCT00310713 Approved Completed Apr 1, 2006 Aug 1, 2006 Prevention of Meningococcal Infection NCT00311415 Phase 3 Completed Oct 1, 2005 Apr 1, 2008 Prevention of Meningococcal Infection NCT00310635 Approved Completed Jun 1, 2005 — Meningococcal Infection NCT00310700 Approved Completed May 1, 2005 Nov 1, 2005 Prevention of Meningococcal Infection NCT00316654 Approved Completed Feb 1, 2005 Oct 1, 2005 Prevention of Meningococcal Infection NCT00310674 Phase 3 Completed Sep 1, 2004 — Prevention of Meningococcal Infection
Competing Products 20 competing products in Prevention of Meningococcal Infection
See all competitors Product Company Stage Hype Score edoxaban + enoxaparin sodium Daiichi Sankyo Phase 3 Mifepristone Eli Lilly Phase 2 EXANTA AstraZeneca Phase 2 Risk of low dose aspirin discontinuation AstraZeneca Pre-clinical DAPA/MET XR + DAPA + MET XR AstraZeneca Phase 3 Esomeprazole + Placebo AstraZeneca Phase 3 PCV15 Merck Pre-clinical Raltegravir Merck Approved RotaTeq (V260) + IPV Merck Phase 3 V501 Merck Phase 3 Zostavax Merck Phase 3 V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920 Merck Phase 3 Letermovir + Placebo Merck Phase 3 Meningococcal C conjugate vaccine Novartis Approved Enteric-coated mycophenolate sodium Novartis Phase 3 Meningococcal C conjugate vaccine Novartis Approved rMenB+OMV NZ Novartis Phase 3 Enteric-Coated Mycophenolate Sodium Novartis Phase 3 Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml Novartis Phase 3 MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation) + MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation) + MenACWY PS (MenACWY-CRM, polysaccharide vaccine) + HBV (Hepatitis B vaccine) + Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197) + MMR (Measles, Mumps and Rubella vaccine) + DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine) + Menjugate (Men C conjugated vaccine) Novartis Phase 2
Other Products from Novartis